Strategic Pharmacokinetic and Demographic Drug Development Initiative
June 2025
Abu Dhabi: The New Capital of Global Pharmacoequity
Over 90% of clinical trials exclude the majority of the world's population, leaving $100 billion in unrealized value every year. The future of pharma is not just discovering new molecules, but unlocking the full value of those we already have.
Even though more than 5,000 peer-reviewed studies show how genetic variations (like CYP2D6, CYP2C9, VKORC1) influence drug metabolism across demographic groups, no global platform exists for population-specific validation at clinical scale, leaving billions at risk of adverse drug reactions. Abu Dhabi, through CoreX, is uniquely positioned to rewrite the rules of drug development.
The Problem
>3,000 Drugs with Unmeasured Risks
Widely used drugs carry unmeasured risks for non-Western patients.
70% Population Variation
of Arab, African, and Asian populations show clinically relevant PK variation, impacting clearance, bioavailability, and toxicity.
$100B Annual Cost
This blind spot drives 20–30% of global adverse drug reactions, resulting in $30–$100 billion annually in avoidable harm and lost productivity.
Example: Over 50% of Emiratis have genetic variants (CYP2C9, VKORC1) that increase the risk of improper warfarin dosing—leading to higher rates of severe bleeding or stroke if Western protocols are used. Precision PK stratification is not a luxury—it's a sovereign health imperative and a significant commercial opportunity.
The Solution: AI-Driven PK Stratification and Demographic-Specific Drug Development, Powered by a Population BioLibrary
Our technology is the only validated platform in the world capable of creating a fully personalized, demographic-specific PK (pharmacokinetics) and drug development system — all starting from a simple blood draw.
CoreX Builds New Drugs for Specific Populations
  • Purpose: Develop new drugs from scratch, designed specifically for each demographic.
  • Our AI rapidly screens thousands of potential new drug candidates, selecting those best suited for each population.
  • From a single blood draw, we generate induced pluripotent stem cells (iPSCs) from carefully chosen individuals representing each group.
  • These cells are turned into mini-organs (liver, heart, kidney) to simulate PK and PD responses — like running "clinical trials on a chip" before human testing.
  • This ensures new drugs are safe, effective, and precisely optimized for diverse populations right from the start.
CoreX Improves Existing Drugs for Safety and Efficacy
  • Purpose: Re-evaluate and improve existing marketed or pipeline drugs for specific populations.
  • Our platform identifies hidden PK risks in existing drugs that were originally designed without considering certain demographic differences.
  • Using organoids made from blood-derived iPSCs of diverse global populations, we test and refine these drugs.
  • This makes them safer, more effective, and opens new value by transforming them into precision therapies tailored to each group.
The Population BioLibrary
At the center of both approaches is the Population BioLibrary — a living, renewable collection of iPSCs and human-derived models or organs (liver, kidney, heart), all created from simple blood draws of representative individuals.
The BioLibrary enables:
  • Continuous, demographic-specific PK and PD testing and refinement.
  • Truly personalized, population-optimized drug development at the cellular level.
  • A sovereign, renewable biological reference for national health security and future innovation.
Strategic Advantage
By using this unique approach, organizations secure:
  • Global leadership in precision PK and demographic-specific drug development.
  • Full control over biological data and development processes.
  • Faster, premium market access with safer, optimized therapies designed specifically for diverse populations.
How It Works
1
AI-Triage (In silico)
Screens thousands of compounds monthly with proprietary AI.
2
Organoid Validation (In vitro)
Tests top candidates on human mini-organs derived from diverse populations.
3
IND-Stage Readiness
Validated candidates proceed to IND documentation, ready for trials.
Why Now?
Regulators worldwide are pivoting toward AI-driven, human-relevant models—our platform is 5 years ahead of this seismic shift.
The underrepresented genetic diversity in global populations is a treasure trove for precision medicine, waiting to be unlocked.
Global pharma giants urgently need validated, population-specific data to unlock new markets and reduce regulatory risk.
Real-World Impact
  • Precision dosing could reduce adverse drug reactions by 30–50%, cut treatment failures by 20–40%, and lower system-wide healthcare costs by 15–25%, while enabling 8–20% premium reimbursement rates on optimized products.
  • Near-term revenue potential: Significant market opportunity with substantial IP value over 3–5 years.
  • Positions implementing regions as global validation hubs for underrepresented populations worldwide.
Value Proposition: Unlocking $100M+/Year in Near-Term Value
A focused, opportunity-mapped analysis of top portfolio drugs reveals $100M+/year in immediate, near-term value from closing pharmacokinetic gaps—representing the first wave of a total $250M/year revenue opportunity as the platform is scaled across all assets and revenue streams. Below are prioritized pathways to capture this value within 12–18 months.
Top 5 Drugs for Rapid Value Capture
Establishing Local Infrastructure Timeline
Competitive Benchmarking
  • Revenue gap: $50M+/year from premium pricing
  • Time-to-market delay: 6–12 months vs. AI-enabled peers
  • This approach closes these gaps in <18 months via sovereign data generation.
Strategic Partnership Value Proposition
Transform existing pharmaceutical assets into precision medicine offerings using biological intelligence (CoreX) + global pharma infrastructure (Strategic Partner). Total Near-Term Revenue: $115M–$245M/year Strategic IP Value: >$500M over 3–5 years
Appendix 1. Contains validation of revenue streams
Evidence-Based Validation
  • Precision Labeling: 8–20% reimbursement premiums (FDA Pharmacogenomic Biomarkers, 2023).
  • Market Access: WHO/IQVIA confirm PK data accelerates formulary inclusion in emerging markets.
  • Licensing Benchmarks: Mid-eight-figure deals for pharmacogenetically stratified drugs (EvaluatePharma, 2022).
  • Govt. Contracts: PEPFAR/WHO initiatives show >$10M/year program budgets.
Recommended Next Steps
  • Prioritize Quick Wins
  • Launch Precision Portfolio Enhancement (Stream #1) with 3–5 high-volume SKUs.
  • Secure Anchor Clients: Target 1–2 government contracts (Stream #5) for social impact + revenue.
  • IP Portfolio Audit: Identify 5–8 molecules for stratification/equity participation (Stream #6).
The Proposal: Strategic Partnership Structure CoreX
(Pre-money valuation: $400M)
Current raise = $100M - $150M, expected to close July 30, 2025
Capital Structure: Strategic Alignment
Mutual Strategic Fit: CoreX & Strategic Partner
Advancing Strategic Priorities
  • Drug Security & Precision: Safer, more effective medicines for diverse global populations, directly supporting drug security and healthcare resilience.
  • Portfolio Value & Revenue: By closing population-specific PK gaps, CoreX unlocks up to $245M/year in near-term revenue and positions partners to command premium pricing and reduce adverse events across their portfolio.
  • Global Leadership: Strategic partners evolve from manufacturer to global validator, positioning themselves as indispensable gateways for population-specific drug validation in $1.5T emerging markets.
Cultural and Operational Compatibility
  • Shared Vision: Alignment on scientific sovereignty, innovation, and building a future-proof, data-driven life sciences sector.
  • Complementary Strengths: Strategic partners bring manufacturing scale and market reach; CoreX provides AI-powered validation and regulatory-ready, population-specific data—enabling seamless integration and rapid impact.
  • Sovereign Data & IP: All validation data and resulting IP remain fully owned by the partner organization, reinforcing strategic independence and compliance with emerging regulatory standards.
Execution and Partnership Dynamics
  • Phase 1: Pilot Project (First 6 Months)
  • Select 3–5 high-impact drugs from partner's portfolio for rapid PK validation using CoreX's AI-organoid platform.
  • Deliver regulatory-grade data and updated labeling for immediate market impact and compliance.
  • Joint task force ensures knowledge transfer and operational alignment with partner teams.
  • Phase 2: Portfolio Scale-Up (6–18 Months)
  • Expand validation to 20+ priority drugs, integrating CoreX workflows into partner's R&D and regulatory processes.
  • Embed data pipelines for real-time PK analytics and adverse event prediction.
  • Begin licensing validated drugs for premium pricing and new market access.
  • Phase 3: Full Integration and Commercialization (18+ Months)
  • Operationalize end-to-end drug intelligence across all manufacturing sites and product lines.
  • Launch population-specific PK index subscriptions and validation services for third parties.
CoreX: The Global Standard in AI-Driven Drug Validation
Our platform integrates advanced artificial intelligence with iPSC—derived miniaturized organ models to generate high-fidelity data on drug organ interactions.
Board & Advisory Powerhouse
Led by Nobel laureate, ex-FDA Science Chair, and ex-CEOs of Pfizer and Biogen. Now validated and embraced by Top-Pharma companies.
Recognised #1 Leader in AI - Longevity and Drug Safety
#1 kidney-on-chip company; and #1 organ-chip data base, Secured exclusive license to MIT-based iPSC liver-on-chip technology, Licensed 2-million-patients biobank, unmatched ability to create iPSCs-organoids, clinical-trial-on-chip.
  • Frost & Sullivan Global Company of the Year in AI-Driven Drug Safety (2024)
  • SCRIP Innovation Award for closing the clinical prediction gap
  • PM360 Innovation Award (AI Category) for revolutionizing data insights
  • Featured by Financial Times, Clarivate, and Citeline as the "holy grail" of AI-powered clinical prediction
The timing of our business is very powerful: The FDA has announced a bold 3-year roadmap to replace animal testing with AI and organoids. We are the recognized leader in this space, and by combining this validated deep-tech with innovation ecosystems including AI, progressive regulatory frameworks, and strong governmental support, we're accelerating the global revolution in personalized drug development and longevity.
Scientific & Clinical Leadership
  • 29 granted or pending patents spanning AI, organoid, and biosensor platforms
  • Two proprietary molecules advancing to clinical trials, targeting longevity and mitochondrial repair
  • Exclusive licenses for iPSC liver-on-chip, kidney-on-chip, and the world's largest diverse IPSC biobank
  • Fully aligned with FDA's 2025 vision to replace animal testing with AI and organoid models
Global Validation Capabilities
  • 50+ validated IPSC lines representing diverse global populations—scaling to 100+ for unmatched coverage
  • 85% accuracy in predicting drug response for underrepresented populations
  • Complete data sovereignty: all data and IP remain fully protected under client ownership, secured by world-class cybersecurity
Call to Action
Strategic anchor partnership opportunity.
Purpose:
To structure a dedicated partnership framework that ensures all joint projects are prioritized in favor of strategic partners before broader pharmaceutical client engagements. This formal commitment also secures early access to CoreX's proprietary PK optimization and portfolio acceleration capabilities, unlocking significant near-term value and strategic advantage.
Next Steps:
  • Formalize the relationship: Execute an LOI or MOU outlining shared objectives, mutual commitments, and prioritization principles.
  • Joint portfolio review: Following agreement, conduct a confidential session with CoreX's scientific and commercial leadership to align on priority molecules and optimization strategies.
  • Define implementation roadmap: Develop a detailed, mutually agreed action plan to advance portfolio value realization and health impact, with phased investment options.
Key Benefits:
  • Priority access to all CoreX programs.
  • Preferential terms and early investment advantages.
  • Strengthened position as a regional and global leader in precision health and PK-driven drug development.
Contact:
Sarah Miller
(971) 56 222 3782
sarah@lifex.ai
Appendix 1.
Precision Medicine Revenue Streams
Precision Portfolio Enhancement ($25M–$50M/year) Evidence:
Stratified drug labeling (e.g., ancestry-specific SKUs) can command 8–20% reimbursement premiums.
Example: A retrospective study found multi-gene pharmacogenomics panels had a 74% reimbursement rate, compared to 43% for single-gene tests—demonstrating payer willingness to pay more for advanced, stratified solutions.
FDA labeling: Drugs like warfarin and clopidogrel require ancestry-informed dosing, supporting premium claims for population-specific products.
Market size: The global precision medicine market is valued at $145B in 2024 and growing at 11.1%–16.5% CAGR, with AI-driven and population-specific solutions as key growth drivers.
Commercial proof: Leading biotech companies logged $1.5M in 2024 revenue and project a clear path to $100M+ within 4 years from similar services.
References: Fueling-the-Global-Shift-to-AI-Powered-Predictive-Drug-Development.pdf Lemke LK et al., Reimbursement of pharmacogenetic tests, PMC10461057
Premium Market Access ($20M–$40M/year) Evidence:
Regional pharmacogenomic and PK data is increasingly required for payer/formulary inclusion, especially in emerging markets.
Reimbursement for pharmacogenetic panels can be significant: up to 74% for multi-gene panels.
Demand for ancestry-informed augmentation is rising, as documented by WHO and IQVIA access reports and reflected in EML criteria for population-specific efficacy.
References: Fueling-the-Global-Shift-to-AI-Powered-Predictive-Drug-Development.pdf Lemke LK et al., PMC10461057
Stratified Licensing Opportunities ($30M–$60M/year) Evidence:
Licensing deals for regionally tailored or stratified drugs are a major growth area, with thousands of deals globally and a 13% CAGR in licensing activity.
Examples:
Novartis–Shanghai Argo (2024): $4.165B total value for cardiovascular RNAi therapies.
Sarepta–Arrowhead (2024): $1.075B for RNAi muscle/CNS therapies.
Discovery-stage and regional licensing deals can reach mid-eight-figure sums per asset, according to industry analyses and deal trackers.
References: BioSpace: Top Biopharma Licensing Deals of 2024
PK Index Infrastructure Sales ($10M–$25M/year) Evidence:
Market size: The global pharmacokinetics services market is valued at $1.19B in 2023–2024, expected to reach $2.32B by 2032, growing at 7.7%–8% CAGR.
Digital PK data subscriptions and analytics can command $250K–$5M per client annually.
Industry example: Certara's Simcyp platform is widely adopted at these price points.
References: Verified Market Research: Pharmacokinetics Services Market IndustryARC: Pharmacokinetics Services Market SNS Insider: Pharmacokinetics Services Market
Government / Health System Contracts ($10M–$30M/year) Evidence:
  • Health data partnerships and population-specific optimization programs with ministries and NGOs often exceed $10M/year per program.
  • Example: PEPFAR (U.S. Global AIDS Coordinator), Annual Partnership Budgets; Global Fund Technical Review Panel Reports (2022–2023).
  • The growing emphasis on health equity and pharmacoequity in emerging markets supports these contract values (WHO Public Health Precision Initiatives, 2023 Strategic Roadmap).
Reference List
  1. Fueling the Global Shift to AI-Powered, Predictive Drug Development
    Industry Report, 2024.
    "Validated and embraced by top Pharma... Leading companies logged $1.5M in 2024 revenue, with a clear growth trajectory to $100M+ in 4 years... 29 patents granted and pending... Frost & Sullivan: Company of the Year 2024 in AI in Drug Safety and Longevity."
  1. Lemke LK et al., "Reimbursement of pharmacogenetic tests at a tertiary academic medical center," 2023.
    "Multi-gene panels achieved a 74% reimbursement rate, compared to 43% for single-gene tests."
    PMC10461057
  1. Precedence Research, "Precision Medicine Market Size, Share, Trends, Report 2024–2034."
    "The global precision medicine market size was valued at $145B in 2024 and is expected to hit $470.53B by 2034, growing at a CAGR of 16.5%."
  1. BioSpace: Top Biopharma Licensing Deals of 2024.
    "Novartis–Shanghai Argo: $4.165B total value for cardiovascular RNAi therapies. Sarepta–Arrowhead: $1.075B for RNAi muscle/CNS therapies."
  1. SNS Insider, "Pharmacokinetics Services Market Size, Share & Growth Report 2024."
    "The global pharmacokinetics services market size was valued at $1.19B in 2023 and is projected to reach $2.32B by 2032, growing at a CAGR of 7.7%."
  1. Certara Inc., Simcyp Product Sheet.
    "Subscription access to proprietary PK simulation datasets ranges from $250K–$5M per user annually."
  1. PEPFAR (U.S. Global AIDS Coordinator), Annual Partnership Budgets; Global Fund Technical Review Panel Reports (2022–2023).
    "Strategic health data partnerships with ministries and NGOs frequently exceed $10M/year per program."
  1. PMC: Drug Repositioning Economics, 2020.
    "Celgene's repositioned thalidomide generated $271M/year after being repurposed for cancer."
  1. WHO Public Health Precision Initiatives, 2023 Strategic Roadmap.
  1. EvaluatePharma, "Pharma Licensing Deal Trends 2022."